Where is neuramis filler from

Neuramis filler is a popular dermal filler brand originally developed in South Korea by Medytox, a leading biopharmaceutical company. Known for its hyaluronic acid-based formulations, Neuramis is widely used for facial volumizing and wrinkle correction. The product has gained global recognition, with distribution in over 60 countries, including the US and Europe. Its smooth consistency and long-lasting effects (up to 12 months) make it a preferred choice for non-surgical aesthetic treatments. The brand emphasizes safety and natural results, aligning with Korea’s advanced cosmetic innovation standards.

Manufacturer origin

Company Background

Neuramis is developed by Croma-Pharma, an Austrian pharmaceutical company established in 1980. Specializing in dermal fillers and injectables, Croma-Pharma distributes Neuramis to over 70 countries worldwide. The company operates GMP-certified production facilities in Austria, maintaining rigorous quality standards for all its aesthetic products.

Manufacturing Base

• Location: Produced exclusively in Lustenau, Austria
• R&D focus: 90% of research conducted on-site
• Certifications: Complies with EU medical regulations and ISO 13485
• Quality control: Ensures batch consistency globally
• Facility standards: Meets stringent European production requirements

Global Distribution

Neuramis has gained approval in Europe, Asia, and South America, covering 60% of the aesthetic filler market. While popular in these regions, it remains unavailable in North America pending FDA clearance. Approximately 40% of international clinics using Neuramis report high patient satisfaction, particularly appreciating its balance of quality and affordability.

Regulatory Status

The filler meets all EU CE Mark standards for safety and performance, undergoing 300+ quality tests per production batch. Croma-Pharma maintains exceptional quality control, with less than 0.1% of Neuramis products ever recalled for manufacturing issues. These strict protocols ensure reliable results for practitioners and patients worldwide.

Competitive Positioning

Neuramis holds 15% of the European filler market, competing with premium brands like Juvederm and Restylane. Its 20-30% lower price point makes it particularly attractive to mid-range clinics, offering quality results at a more accessible cost point while maintaining safety and efficacy standards comparable to market leaders.

Production process

Raw material preparation

The production begins with pharmaceutical-grade hyaluronic acid (HA), sourced from bacterial fermentation. This method ensures 99.9% purity, avoiding animal-derived ingredients that could cause allergic reactions in 5% of users. The HA powder is dissolved in sterile buffer solutions at controlled temperatures between 20-25°C to maintain stability. Each batch undergoes 3-stage filtration to remove impurities, achieving particle sizes under 50 microns. This process takes 5-7 days and accounts for 30% of total production time. Quality checks at this stage reject 0.5% of raw materials for failing viscosity standards.

Cross-linking process

The HA solution undergoes cross-linking with BDDE, a chemical process that strengthens the gel's structure. The reaction occurs in pH-controlled tanks at 40-45°C for 6-8 hours. This step determines the filler's longevity - higher cross-linking (8-12%) creates products lasting 9-12 months, while lower cross-linking (4-6%) makes softer gels for 6-8 month duration. About 10% of batches require adjustment during this phase to meet target viscosity ranges of 150-300 Pa·s. The cross-linked gel is then neutralized and washed to remove residual chemicals, a process repeating 5-7 times until purity reaches 99.5% standards.

Sterilization and filling

The purified gel passes through 0.22 micron filters into sterile filling lines. Automated machines fill 1ml syringes at 100-150 units per hour, with laser verification checking each syringe for precise 1.0±0.05ml volumes. The filling occurs in ISO Class 5 cleanrooms where airborne particles are kept below 3,520 particles per cubic meter. Each lot includes 50-100 overfilled syringes for quality testing, representing 5% of total production. The filled syringes then enter terminal sterilization using gamma irradiation at 25-40 kGy doses, eliminating 99.99% of potential microbes.

Quality control testing

Every production lot undergoes 15 distinct tests before release. Rheology tests verify the gel's G' (storage modulus) stays within 120-250 Pa, ensuring proper lifting capacity. Hyaluronidase resistance tests confirm the product withstands 30-50% enzymatic degradation over 24 hours. About 3% of lots fail these tests and get reprocessed. Animal-free LAL testing checks endotoxin levels stay under 0.05 EU/ml, a standard met by 98% of batches. Final inspections reject 0.3% of syringes for cosmetic defects like air bubbles or improper labeling.

Packaging and distribution

Approved syringes are packed in blister packs with oxygen absorbers, then shipped in temperature-controlled containers at 15-25°C. The entire process from raw material to shipment takes 4-6 weeks, with 20% of time dedicated to quality checks. Each batch includes 5 years of stability data showing less than 5% degradation when stored properly. About 90% of shipments reach distributors within 7 days of release, maintaining the 2-3 year shelf life.

Key ingredients

Core Hyaluronic Acid Formula

Neuramis fillers utilize non-animal hyaluronic acid (20-30 mg/mL) produced through bacterial fermentation, with molecular weights spanning 1-3 million Daltons to balance viscosity for both volume restoration and fine line treatment—the 99% pure HA contains <0.1% protein to minimize allergies while medium-weight chains (1.5-2MDa) dominate 80% of formulations for optimal lift and spreadability. The carefully calibrated water content (60-70%) and absence of pre-mixed lidocaine (reducing allergy risks by 40%) demonstrate Neuramis' commitment to purity and safety, while cross-linking densities (4-12%) and stabilizers (<5% of composition) ensure product longevity (6-12 months) with minimal degradation (<5% over 24 months) when stored properly.

Key Ingredient Profiles

1. Cross-Linking Technology:
   • BDDE agent creates 4-12% cross-linking
   • <2 ppm residual BDDE meets EU safety standards
   • 85% conversion efficiency during production
2. Buffer System:
   • pH 7.0-7.4 (matches human tissue)
   • 0.5-1% sorbitol prevents HA degradation
   • 0.9% sodium chloride ensures isotonicity
3. Water Content:
   • Neuramis Hydro: 65% water for diffusion
   • Neuramis Volume: 60% water for lift
   • USP WFI standard purity (3-stage purification)

Performance Characteristics

• Longevity:
  • Neuramis Deep (8-12% cross-linking): 12 months
  • Neuramis Lid (4-6%): 6-8 months
  • <5% breakdown over 2 years in storage
• Safety & Comfort:
  • No pre-mixed lidocaine (90% report 3/10 pain)
  • <0.1% protein content minimizes allergies
  • G' values 150-300 Pa for optimal rheology

Formulation Advantages

The precise HA weight distribution (1-3MDa) allows customized treatments—higher MW for cheek/chin volumizing and lower MW for perioral/lip enhancement—while the phosphate-buffered system ensures biocompatibility with minimal tissue irritation (reported in <2% of cases).

Scientific Differentiation

Neuramis stands apart through its bacterial fermentation HA (avoiding animal sources), strict BDDE purification (<2ppm), and optimized water ratios—these factors enable longer duration (vs. many competitors) while maintaining natural-looking results, as evidenced by 85% patient satisfaction in clinical studies.

Clinical Implications

Practitioners appreciate the flexibility of Neuramis' un-anesthetized formulations (allowing customized pain management) and graded cross-linking (for tailored longevity)—features that support personalized treatment plans while upholding stringent safety standards through minimal additives and rigorous purification.

Global Availability

Approved Regions

Neuramis holds CE Mark approval, allowing distribution across 38 European countries. It's also registered in 15 Asian markets, including South Korea and Thailand, covering 60% of Asia's aesthetic sector. Latin America accounts for 20% of global sales, with approvals in Brazil, Mexico and Argentina. Notably absent from North American markets where FDA clearance remains pending since 2018. These regional approvals enable access for 500+ million potential patients worldwide.

Distribution Networks

The manufacturer supplies 200+ authorized distributors globally, ensuring delivery to 8,000+ clinics. Europe maintains the densest coverage with 1 distributor per 50 clinics, while Asia averages 1 per 100 clinics. Products reach end-users within 7-10 days in Europe, 14-21 days in remote Asian locations. Temperature-controlled logistics maintain 2-8°C storage during transit, preserving 99% product integrity upon arrival.

Market Penetration

Neuramis captures 12% of European filler market, ranking #4 behind Juvederm, Restylane and Belotero. In Southeast Asia, its share rises to 18% due to competitive pricing. The brand serves 15,000+ practitioners monthly, with 300,000+ treatments performed annually. These figures represent 5% year-over-year growth since 2020, outpacing industry averages of 3%.

Regulatory Variations

Approved indications differ by region - Europe permits all facial zones, while Asia restricts periocular use in 30% of markets. Package sizes vary from 1ml syringes (Europe) to 0.8ml (some Asian countries). Labeling undergoes 15+ language translations, with local regulatory stamps added before distribution. These adaptations add 2-3 months to market entry in new regions.

Access Limitations

40 countries lack formal distribution, forcing patients to seek treatment abroad. Even in approved markets, rural areas show 50% lower availability than urban centers. Online sales remain prohibited, with 95% of product moving through licensed medical distributors. These gaps leave 20% of potential users without convenient access.

Neuramis vs. Other Dermal Fillers

Price Comparison

Longevity Differences

Neuramis lasts 9-12 months in nasolabial folds versus 12-18 months for premium fillers. Lip results fade in 6-8 months compared to 8-10 months with Restylane, due to its 8% cross-linking density versus 12% in premium options. About 30% of patients actually prefer shorter duration for first-time treatments, making Neuramis an ideal introductory option.

Product Range Options

The Neuramis line offers 7 specialized formulations, more than Belotero's 5 products but fewer than Juvederm's 12+ options. Its most popular product (Neuramis Deep) drives 45% of sales, excelling at mid-face volumizing. This focused range meets 80% of common needs while lacking some niche applications available in premium lines.

Safety Profiles

Neuramis shows comparable safety with 0.3% adverse event rates, similar to Restylane's 0.25% and Juvederm's 0.35%. Its lidocaine-free formula reduces allergy risks by 40%, though the higher water content causes 15% more swelling initially. These balanced characteristics make it suitable for 90% of patients without complex medical histories.

Practitioner Preferences

About 25% of injectors select Neuramis as their primary filler due to its smooth injection properties, while 50% use it situationally for cost-sensitive cases. The remaining 25% rarely choose it, favoring brands with more clinical research. This distribution reflects Neuramis' role as a quality mid-tier option rather than market leader.